View Item 

Show simple item record

Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer
dc.contributor.authorHage, Andrew N.
dc.contributor.authorCapriccioso, Christina
dc.contributor.authorBrennan, Julia
dc.contributor.authorHeiden, Brendan
dc.contributor.authorZheutlin, Alexander
dc.contributor.authorSabel, Michael S.
dc.date.accessioned2017-12-15T16:47:57Z
dc.date.available2019-01-07T18:34:36Zen
dc.date.issued2017-11
dc.identifier.citationHage, Andrew N.; Capriccioso, Christina; Brennan, Julia; Heiden, Brendan; Zheutlin, Alexander; Sabel, Michael S. (2017). "Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer." Journal of Surgical Oncology 116(6): 665-670.
dc.identifier.issn0022-4790
dc.identifier.issn1096-9098
dc.identifier.urihttps://hdl.handle.net/2027.42/139969
dc.publisherWiley Periodicals, Inc.
dc.subject.otherbreast conservation
dc.subject.othermastectomy
dc.subject.otherneoadjuvant chemotherapy
dc.subject.otherluminal A
dc.titleImpact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelSurgery and Anesthesiology
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139969/1/jso24721.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139969/2/jso24721_am.pdf
dc.identifier.doi10.1002/jso.24721
dc.identifier.sourceJournal of Surgical Oncology
dc.identifier.citedreferenceFisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy findings from the national surgical adjuvant breast and bowel project (NSABP) protocol B‐18. Cancer. 2002; 95: 681 – 695.
dc.identifier.citedreferenceFisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 2672 – 2685.
dc.identifier.citedreferenceKong X, Moran MS, Zhang N, et al. Meta‐analysis confirms achieving pathological complete response after neoadjvuant chemtoherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2084; 47: 2084 – 2090.
dc.identifier.citedreferenceSorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001; 98: 10869 – 10874.
dc.identifier.citedreferencePerou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747 – 752.
dc.identifier.citedreferenceBrenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application ? J Clin Oncol. 2005; 23: 7350 – 7360.
dc.identifier.citedreferenceHoussami N, Macaskill P, Von Minckwitz G, et al. Meta‐analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012; 48: 3342 – 3354.
dc.identifier.citedreferenceHarbeck N, Thomssen C, Gnant M, Gallen ST. Brief preliminary summary of the consensus discussion. Breast Care. 2013; 8: 102 – 109.
dc.identifier.citedreferenceKaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: reveiw and recommendations. J Clin Oncol. 2003; 21: 2600 – 2608.
dc.identifier.citedreferenceLoibl S, von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006; 13: 1434 – 1442.
dc.identifier.citedreferenceMamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016; 23: 3467 – 3474.
dc.identifier.citedreferenceKelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identificationa nd classification after neoadjuvant chemotherapy—systematic review and meta analysis. Acad Radiol. 2009; 16: 551 – 563.
dc.identifier.citedreferenceRouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients wtih T1‐T2 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002; 20: 1304 – 1310.
dc.identifier.citedreferenceCortazar P, Zhang L, Untch M, et al. Pathological complete response and long‐term clinical benefit in breast cancer: the CTNeoBCpooled analysis. Lancet. 2014; 384: 164 – 172.
dc.identifier.citedreferenceLips EH, Mulder L, de Ronde JJ, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013; 140: 63 – 71.
dc.identifier.citedreferenceColleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004; 10: 6622 – 6628.
dc.identifier.citedreferenceFaneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003; 88: 406 – 412.
dc.identifier.citedreferenceRing AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Bri J Cancer. 2004; 91: 2012 – 2017.
dc.identifier.citedreferenceTan MC, Al Mushawah F, Gao F, et al. Predictors of complete pathological response after neoadjuvant systemc therapy for breast cancer. Am J Surgery. 2009; 198: 520 – 525.
dc.identifier.citedreferenceBoughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast‐conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014; 260: 608 – 616.
dc.identifier.citedreferenceSpring LM, Gupta A, Reynolds KL. Neoadjuvant endocrine therapy for estrogen receptor‐positive breast cancer. JAMA Oncol. 2016; 2: 1477 – 1486.
dc.identifier.citedreferenceCardoso F, van’t Veer LJ, Bogaerts J, et al. 70‐gene signature as an aid to treatment decisions in early‐stage breast cancer. N Engl J Med. 2016; 375: 717 – 729.
dc.identifier.citedreferenceSoran A, Bhargava R, Johnson R, et al. The impact of Oncotype DX recurrence score of paraffin‐embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Dis. 2016; 36: 65 – 71.
dc.identifier.citedreferenceFisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local‐regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B‐18. J Clin Oncol. 1997; 15: 2483 – 2493.
dc.identifier.citedreferenceBaer HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative deocetaxel added to preoperative doxorubicin plus cyclophosphamide for operatibe breast cancer. NSABP Project Protocol B‐27. J Clin Oncol. 2006; 24: 2019 – 2027.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jso24721.pdf
Size:
349.5KB
Format:
PDF
View/Open
Name:
jso24721_am.pdf
Size:
229.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.